Will This Analyst Upgrade Help Clovis Oncology (CLVS) Stock Today? (Update)

Update (9:35 a.m.): Updated with Thursday market open information.

NEW YORK (TheStreet) -- Stifel Nicolaus upgraded Clovis Oncology  (CLVS) to "buy" from "hold" and set a $50 price target. The firm cited valuation, as the stock is down 60% from its highs.

The stock was up 4.45% to $40.11 at 9:32 a.m. on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CLVS Chart

CLVS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition